A Phase 3 Trial of brepocitinib in dermatomyositis
Por: Lundberg, Ingrid E
Tipo de material: 
TextoIdioma: Inglés Descripción: páginas: 1953-1955Tema(s): ALERGIA | INMUNOLOGÍA GENERAL | ENFERMEDAD AUTOINMUNE | DERMATOLOGÍA GENERAL | ENFERMEDAD PULMONAR INTERSTICIAL | ENFERMEDAD NEUROMUSCULAR | NEUROLOGÍA | NEUROCIRUGÍA | CÉLULAS T
En: The New England Journal of MedicineResumen: Dermatomyositis is a subgroup of idiopathic inflammatory myopathies — systemic autoimmune disorders that are typically characterized by the involvement of multiple organs, including muscle, skin, joints, lungs, gastrointestinal tract, and heart — all conditions with high morbidity and mortality. Treatment of myositis is based on off-label use of high doses of glucocorticoids, usually over long periods of time, in combination with immune-modulating agents and physical exercise. However, the outcome is often disappointing, with persisting inflammation and recurrent flares.
| Tipo de ítem | Ubicación actual | Colección | Signatura | Info Vol | Estado | Fecha de vencimiento | Código de barras |
|---|---|---|---|---|---|---|---|
Títulos de Revistas
|
Biblioteca Central ESSALUD | Colección General | NEJM (Navegar estantería) | Vol.394, No.19 (2026) | Disponible | NEJM014 |
Dermatomyositis is a subgroup of idiopathic inflammatory myopathies — systemic autoimmune disorders that are typically characterized by the involvement of multiple organs, including muscle, skin, joints, lungs, gastrointestinal tract, and heart — all conditions with high morbidity and mortality. Treatment of myositis is based on off-label use of high doses of glucocorticoids, usually over long periods of time, in combination with immune-modulating agents and physical exercise. However, the outcome is often disappointing, with persisting inflammation and recurrent flares.